FOXO TECHNOLOGIES INC.’S BEHAVIORAL HEALTH SUBSIDIARY HAS BEEN APPROVED TO RECEIVE SCOTT COUNTY OPIOID ABATEMENT FUNDS
FOXO Technologies Inc. (NYSE American: FOXO) announced that its behavioral health subsidiary, Myrtle Recovery Centers, has secured approval for Scott County Opioid Abatement Funds for a second consecutive year. The funding, effective July 1, 2025, will support care for uninsured patients from Scott County at the company's Oneida, Tennessee facility.
The facility is currently operating at full capacity with a patient waiting list, demonstrating strong demand for its services. Myrtle's CEO Robert Merritt highlighted this as validation of their clinical team's quality of care. FOXO's CEO Seamus Lagan indicated plans for expansion through organic growth and acquisitions, expecting Myrtle to become a significant revenue contributor to FOXO in the future.
FOXO Technologies Inc. (NYSE American: FOXO) ha annunciato che la sua controllata nel settore della salute comportamentale, Myrtle Recovery Centers, ha ottenuto per il secondo anno consecutivo l'approvazione dei fondi per la riduzione degli oppioidi della contea di Scott. Il finanziamento, attivo dal 1° luglio 2025, sosterrà l'assistenza ai pazienti non assicurati della contea di Scott presso la struttura dell'azienda a Oneida, Tennessee.
La struttura sta attualmente operando a piena capacità con una lista d'attesa, a dimostrazione della forte domanda per i suoi servizi. Il CEO di Myrtle, Robert Merritt, ha sottolineato che ciò conferma la qualità dell'assistenza offerta dal loro team clinico. Il CEO di FOXO, Seamus Lagan, ha indicato piani di espansione tramite crescita organica e acquisizioni, prevedendo che Myrtle diventerà un importante contributore ai ricavi di FOXO in futuro.
FOXO Technologies Inc. (NYSE American: FOXO) anunció que su subsidiaria de salud conductual, Myrtle Recovery Centers, ha asegurado la aprobación de los Fondos para la Reducción de Opioides del Condado de Scott por segundo año consecutivo. La financiación, vigente a partir del 1 de julio de 2025, apoyará la atención a pacientes no asegurados del Condado de Scott en la instalación de la empresa en Oneida, Tennessee.
La instalación actualmente opera a plena capacidad con una lista de espera de pacientes, lo que demuestra una fuerte demanda por sus servicios. El CEO de Myrtle, Robert Merritt, destacó esto como una validación de la calidad de atención de su equipo clínico. El CEO de FOXO, Seamus Lagan, indicó planes de expansión mediante crecimiento orgánico y adquisiciones, esperando que Myrtle se convierta en un contribuyente significativo a los ingresos de FOXO en el futuro.
FOXO Technologies Inc. (NYSE American: FOXO)는 자사의 행동 건강 자회사인 Myrtle Recovery Centers가 Scott 카운티 오피오이드 감축 기금 승인을 2년 연속 확보했다고 발표했습니다. 2025년 7월 1일부터 적용되는 이 자금은 테네시주 오니다에 위치한 회사 시설에서 Scott 카운티의 보험 미가입 환자 치료를 지원할 예정입니다.
이 시설은 현재 만원으로 운영 중이며 대기자 명단이 있을 정도로 서비스에 대한 수요가 높습니다. 마이틀의 CEO인 로버트 메릿은 이를 임상 팀의 높은 치료 품질을 입증하는 증거로 강조했습니다. FOXO의 CEO 셰이머스 라간은 유기적 성장과 인수를 통한 확장 계획을 밝혔으며, 마이틀이 앞으로 FOXO의 주요 수익원이 될 것으로 기대하고 있습니다.
FOXO Technologies Inc. (NYSE American : FOXO) a annoncé que sa filiale spécialisée en santé comportementale, Myrtle Recovery Centers, a obtenu pour la deuxième année consécutive l'approbation des fonds d'atténuation des opioïdes du comté de Scott. Ce financement, effectif à partir du 1er juillet 2025, soutiendra les soins aux patients non assurés du comté de Scott dans l'établissement de l'entreprise à Oneida, Tennessee.
L'établissement fonctionne actuellement à pleine capacité avec une liste d'attente, témoignant d'une forte demande pour ses services. Le PDG de Myrtle, Robert Merritt, a souligné que cela valide la qualité des soins prodigués par leur équipe clinique. Le PDG de FOXO, Seamus Lagan, a indiqué des projets d'expansion par croissance organique et acquisitions, prévoyant que Myrtle deviendra un contributeur important aux revenus de FOXO à l'avenir.
FOXO Technologies Inc. (NYSE American: FOXO) gab bekannt, dass seine Tochtergesellschaft im Bereich Verhaltensgesundheit, Myrtle Recovery Centers, zum zweiten Mal in Folge die Genehmigung für die Opioid-Abbaumittel des Scott County erhalten hat. Die Finanzierung, wirksam ab dem 1. Juli 2025, wird die Versorgung von nicht versicherten Patienten aus dem Scott County in der Einrichtung des Unternehmens in Oneida, Tennessee, unterstützen.
Die Einrichtung arbeitet derzeit mit voller Kapazität und hat eine Warteliste, was die hohe Nachfrage nach ihren Dienstleistungen zeigt. Robert Merritt, CEO von Myrtle, hob hervor, dass dies die Qualität der Versorgung durch ihr klinisches Team bestätigt. Seamus Lagan, CEO von FOXO, kündigte Expansionspläne durch organisches Wachstum und Übernahmen an und erwartet, dass Myrtle zukünftig ein bedeutender Umsatzträger für FOXO wird.
- None.
- None.
WEST PALM BEACH, FLORIDA, June 30, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc., has been approved to receive Scott County Opioid Abatement Funds for a second year, starting July 1, 2025 to provide care for uninsured patients from Scott County, at its Oneida, Tennessee location.
Robert Merritt, Chief of Executive Officer of Myrtle stated, “We appreciate the support from Scott County to provide care for uninsured patients from the community that might otherwise not receive the care they need. To receive this support for a second year running combined with our facility operating at capacity and with a waiting list of patients is an acclamation for the quality of care our clinical team provides. We look forward to further expanding our footprint and offering our proven clinical program to an expanded patient base”
Seamus Lagan, Chief Executive Officer of parent company, FOXO Technologies Inc., further added, “We are pleased at how Myrtle has ramped up operations and made a significant impact in the rural communities it serves. We look forward to expanding Myrtle into additional locations through organic growth and acquisition and believe this subsidiary will contribute significant revenue and value to FOXO in future years. Furthermore as we exit the first half of the year we are excited for the second half of 2025 and look forward to demonstrating continued successes achieved in the second quarter, in our upcoming quarterly report to June 30th, when filed”
About FOXO Technologies Inc. (“FOXO”)
FOXO owns and operates three subsidiaries.
Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical), a critical access designated (CAH) hospital in East Tennessee.
Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for detox and residential treatment and outpatient services for MAT and OBOT Programs.
FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.
For more information about FOXO, visit www.foxotechnologies.com.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the FOXO’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; the ability to implement FOXO’s business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans; the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
Sebastien Sainsbury
ssainsbury@foxotechnologies.com
(561) 485-0151
FAQ
What funding has FOXO Technologies' Myrtle Recovery Centers received for 2025?
How is FOXO's Myrtle Recovery Centers performing in terms of capacity?
What are FOXO Technologies' expansion plans for Myrtle Recovery Centers?
When will FOXO Technologies (NYSE: FOXO) report its Q2 2025 results?
Where is Myrtle Recovery Centers' current facility located?
